Our previous studies showed that IL‐38 can alleviate liver, spleen, and kidney enlargement in lupus mice, reverse lupus‐like pathological changes, improve immune homeostasis imbalance, and inhibit the occurrence and development of lupus through regulating ERK1/2, JNK1/2, p38, NF‐κB p65, and STAT5 signaling pathways [21]. This evidence concerns the gene NFKB1 and systemic lupus erythematosus.